Log in
GABA-B receptor agonist

Phenibut

Phenibut (β-phenyl-γ-aminobutyric acid) is a GABA-B receptor agonist and neuropsychotropic agent structurally related to baclofen. Originally developed in Russia as an anxiolytic and nootropic, it is not FDA-approved in the United States but is widely available as a dietary supplement. The most testable fact is its high potential for tolerance, dependence, and severe withdrawal syndrome resembling alcohol or benzodiazepine withdrawal.

Practice questionsHigh-yield facts
Drug classGABA-B receptor agonist, anxiolytic, nootropic
MechanismAgonizes GABA-B receptors; crosses blood-brain barrier via LAT1
Main usesAnxiety, insomnia, cognitive enhancement (not FDA-approved in US)
Key adverse effectSevere physical dependence and withdrawal syndrome
5 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Phenibut is a structural analogue of γ-aminobutyric acid (GABA) with a phenyl ring attached to the beta carbon, enabling it to cross the blood-brain barrier via the large neutral amino acid transporter 1 (LAT1). Once in the central nervous system, phenibut acts primarily as a GABA-B receptor agonist, similar to baclofen but with lower affinity.

The GABA-B receptor is a metabotropic G-protein coupled receptor that mediates inhibitory neurotransmission through:

  • Activation of inwardly rectifying potassium channels (hyperpolarization)
  • Inhibition of voltage-gated calcium channels (reduced neurotransmitter release)
  • Decreased presynaptic neurotransmitter release in multiple systems

At higher doses, phenibut may also interact with α2δ subunit-containing voltage-dependent calcium channels, similar to gabapentinoids (pregabalin, gabapentin), contributing to its anxiolytic and anticonvulsant-like effects. Some evidence suggests weak dopaminergic activity, which may account for mild stimulant or euphoric effects reported at certain doses.

High-yield for exams
  • Phenibut is a GABA-B agonist structurally related to baclofen; crosses BBB via LAT1 transporter.
  • Not FDA-approved in the US; sold as a dietary supplement with no quality control.
  • Causes rapid tolerance and severe physical dependence, even with short-term daily use.
  • Withdrawal resembles alcohol/benzodiazepine withdrawal: tremor, tachycardia, seizures, delirium.
  • Not detected on standard urine drug screens; diagnosis is clinical and history-based.
  • Managed with gradual taper over weeks to months; baclofen or benzodiazepines may be used for cross-taper.
  • Major risk in combination with alcohol, benzodiazepines, or opioids: severe CNS/respiratory depression.
  • Think phenibut in young adults with unexplained withdrawal syndrome and history of nootropic or supplement use.

Indications

Phenibut is not approved by the FDA for any medical indication in the United States and is marketed as a dietary supplement. In Russia and some former Soviet states, it has regulatory approval for:

  • Anxiety disorders
  • Insomnia
  • Post-traumatic stress disorder
  • Asthenia (chronic fatigue)
  • Vestibular disorders and motion sickness
  • Alcohol withdrawal symptoms
  • Stuttering in children

In the US and Europe, phenibut is used off-label or recreationally for:

  • Self-treatment of social anxiety
  • Cognitive enhancement (nootropic use)
  • Sleep aid
  • Recreational sedation or euphoria

The lack of FDA oversight means quality, purity, and dosing consistency vary widely among commercially available products. Clinicians should be aware of phenibut use when evaluating patients with unexplained sedation, withdrawal syndromes, or polysubstance use.

Pharmacokinetics

Absorption: Phenibut is well absorbed orally, with effects typically beginning 2–4 hours after ingestion due to LAT1-mediated transport across the blood-brain barrier. Peak plasma concentrations occur approximately 3–5 hours post-dose.

Distribution: It crosses the blood-brain barrier efficiently. Volume of distribution and protein binding data in humans are limited.

Metabolism: Phenibut undergoes minimal hepatic metabolism. The majority is excreted unchanged in urine.

Elimination: Renal excretion is the primary route of elimination. The elimination half-life is approximately 5–6 hours, but CNS effects may persist longer due to receptor binding kinetics. Clearance is reduced in renal impairment, increasing risk of accumulation and toxicity.

Special populations: Data on pediatric, geriatric, hepatic, and renal impairment populations are sparse. Dose reduction is prudent in renal dysfunction.

Adverse effects

Phenibut's adverse effect profile resembles other GABAergic agents, with significant concern for dependence and withdrawal.

Common adverse effects

  • Sedation, drowsiness, fatigue
  • Dizziness, headache
  • Nausea, vomiting
  • Agitation or irritability (paradoxical in some patients)
  • Confusion, impaired coordination

Serious adverse effects

  • Physical dependence: Develops rapidly, sometimes within weeks of daily use
  • Tolerance: Significant tolerance develops, prompting dose escalation
  • Withdrawal syndrome: Can be severe and life-threatening, resembling alcohol or benzodiazepine withdrawal (onset 3–24 hours after last dose)
  • Tremor, tachycardia, hypertension
  • Severe anxiety, panic attacks
  • Hallucinations, delirium
  • Seizures (most concerning complication)
  • Insomnia, diaphoresis
  • Hepatotoxicity: Case reports of acute liver injury
  • Eosinophilia and fatty liver degeneration: Rare but reported
  • Respiratory depression: Especially in overdose or combination with other CNS depressants

Overdose

Presents with profound CNS depression, respiratory depression, hypothermia, and bradycardia. Management is supportive; no specific antidote exists. Baclofen overdose protocols (supportive care, possible benzodiazepines for seizures) may be applicable.

Contraindications and warnings

Absolute contraindications:

  • Known hypersensitivity to phenibut or related compounds

Relative contraindications and warnings:

  • Renal impairment: Reduced clearance increases toxicity risk
  • Hepatic impairment: Limited data, but hepatotoxicity has been reported
  • History of substance use disorder: Very high risk of dependence
  • Pregnancy and lactation: No human data; avoid use (Category C equivalent in risk classification)
  • Pediatric use: Safety and efficacy not established in children outside limited Russian literature
  • Geriatric use: Increased risk of sedation, falls, and cognitive impairment

Black box equivalent warnings (if phenibut were FDA-regulated):

  • Risk of severe physical dependence and life-threatening withdrawal: Abrupt discontinuation after regular use can cause seizures, delirium, and autonomic instability. Tapering over weeks to months is essential.
  • Abuse potential: Scheduled in some countries (e.g., Australia, Hungary) due to misuse.

Patients should be counseled about the risks of daily use, tolerance, and the need for medically supervised discontinuation.

Drug interactions

Phenibut has significant potential for pharmacodynamic interactions due to its CNS depressant effects.

Major interactions

  • Alcohol: Additive CNS depression, respiratory depression, risk of overdose
  • Benzodiazepines: Additive GABAergic effects, increased sedation and respiratory depression
  • Opioids: Severe CNS and respiratory depression; potentially fatal
  • Barbiturates: Profound sedation and respiratory compromise
  • Baclofen: Additive GABA-B agonism; risk of excessive sedation and hypotonia
  • Other GABAergic drugs (e.g., gabapentinoids, Z-drugs): Enhanced sedation

Moderate interactions

  • Antipsychotics: Increased sedation, orthostatic hypotension
  • Antihistamines (sedating types): Additive sedation
  • Muscle relaxants: Additive CNS depression
  • Antihypertensives: Possible additive hypotensive effects

CYP450 interactions: Phenibut undergoes minimal hepatic metabolism, so cytochrome P450-mediated interactions are unlikely. However, polypharmacy involving CNS depressants is high-risk.

Clinicians should obtain a thorough substance use history, including supplement use, when evaluating unexplained sedation or withdrawal syndromes.

Clinical pearls

  • Phenibut is not FDA-approved but widely available online as a "nootropic" or dietary supplement, leading to unregulated use and increasing emergency department presentations.
  • Withdrawal can be life-threatening: Resembles alcohol or benzodiazepine withdrawal with seizures as the most dangerous complication. Taper protocols are similar: gradual dose reduction over weeks to months, often with adjunctive benzodiazepines or baclofen (another GABA-B agonist) for symptom control.
  • Tolerance develops rapidly: Users often escalate from low initial doses to high daily doses within weeks, increasing toxicity and withdrawal severity.
  • LAT1 transporter: The phenyl group enables BBB penetration via the large neutral amino acid transporter, distinguishing it from GABA itself (which does not cross the BBB).
  • Baclofen as a substitute: In withdrawal management, baclofen (a prescription GABA-B agonist) can be used as a cross-taper agent, though dosing equivalence is not well established.
  • Drug screens: Phenibut is not detected on standard urine drug screens. Diagnosis relies on history and clinical presentation.
  • Case reports: Include seizures, acute liver injury, altered mental status, and eosinophilia. Always consider phenibut in unexplained withdrawal or CNS depression, especially in younger patients using supplements.
  • International status: Scheduled or restricted in Australia, Hungary, Italy, and Lithuania due to abuse potential. In the US, the FDA has issued warnings but has not scheduled it under the Controlled Substances Act.
  • Exam tip: High-yield association is a patient presenting with anxiety, using "supplements for focus," who develops severe withdrawal (tremor, tachycardia, seizures) when they stop taking them. Think phenibut or kratom in such scenarios.
Mnemonic

PHENIBUT withdrawal = PHENobarbital-like: Physical dependence, Hypertension, Extreme agitation, Neurologic (seizures), Insomnia, BBB penetration (via LAT1), Unregulated supplement, Taper required.

Practice questions

1. A 24-year-old man presents to the emergency department with tremor, diaphoresis, and agitation. He reports using a 'cognitive enhancement supplement' daily for the past 3 months but ran out 2 days ago. Vital signs: BP 165/95 mm Hg, HR 115 bpm, temp 37.8°C. He appears anxious and has a coarse tremor. Urine drug screen is negative. Which of the following is the most likely diagnosis?

Answer: C. Phenibut withdrawal is the most likely diagnosis given the history of daily 'nootropic' or supplement use, negative urine drug screen, and presentation with autonomic hyperactivity (hypertension, tachycardia, diaphoresis) and tremor. Phenibut is widely sold as a cognitive supplement and causes GABAergic withdrawal similar to alcohol or benzodiazepines, but it is not detected on standard drug screens. Alcohol and benzodiazepine withdrawal would typically be identified by history or detected on screening. Amphetamine intoxication would show positive urine drug screen and typically presents with more pronounced psychomotor agitation and hyperthermia. Hyperthyroidism would not have acute onset related to supplement cessation.

2. A 30-year-old woman is brought to the clinic by her partner due to increasing confusion and sedation over the past week. She has been taking phenibut daily for 4 months and recently increased her dose due to 'loss of effect.' She also takes alprazolam twice daily for anxiety. On exam, she is somnolent but arousable, with slurred speech and ataxia. Which of the following best explains her presentation?

Answer: C. The patient's presentation of excessive sedation, confusion, slurred speech, and ataxia is most consistent with additive CNS depression from concurrent use of phenibut (a GABA-B agonist) and alprazolam (a benzodiazepine acting at GABA-A receptors). Both agents enhance GABAergic inhibition through different mechanisms, and their combination significantly increases sedation and risk of respiratory depression. While phenibut tolerance is occurring (evidenced by dose escalation), the acute worsening is due to dangerous polypharmacy. Benzodiazepine overdose alone would not explain the chronic escalation pattern. Hepatic encephalopathy is possible but less likely without other signs of liver failure. This combination is never a normal therapeutic effect and represents a serious drug interaction.

3. A 28-year-old man with a history of phenibut use disorder is admitted for medically supervised withdrawal. He has been taking high daily doses for 6 months. Which of the following is the most appropriate initial management strategy?

Answer: B. Gradual phenibut taper over several weeks (typically 2–8 weeks depending on dose and duration) with seizure precautions is the most appropriate management for phenibut withdrawal. Abrupt discontinuation carries high risk of life-threatening complications including seizures and delirium. While baclofen (another GABA-B agonist) can be used as a cross-taper agent, immediate switching without gradual transition is not standard; more commonly, phenibut itself is tapered or a careful cross-taper to baclofen is performed. Methadone is used for opioid use disorder, not GABAergic withdrawal. Haloperidol alone does not address the underlying GABAergic withdrawal and may lower seizure threshold. Benzodiazepines are often added as adjunctive therapy during the taper to manage withdrawal symptoms.

Frequently asked questions

How does phenibut work?

Phenibut works primarily as a GABA-B receptor agonist, producing inhibitory effects in the central nervous system by activating potassium channels and inhibiting calcium channels. Its phenyl group allows it to cross the blood-brain barrier via the LAT1 transporter, unlike GABA itself. At higher doses, it may also interact with voltage-gated calcium channels similar to gabapentinoids, contributing to anxiolytic and sedative effects.

What are the side effects of phenibut?

Common side effects include sedation, dizziness, nausea, and headache. Serious adverse effects include rapid development of physical dependence and tolerance, often within weeks. The most dangerous complication is severe withdrawal syndrome resembling alcohol or benzodiazepine withdrawal, which can include seizures, delirium, tachycardia, hypertension, and hallucinations. Hepatotoxicity and respiratory depression (especially in overdose or with other CNS depressants) have also been reported.

Is phenibut a controlled substance?

Phenibut is not a controlled substance under the US Controlled Substances Act and is sold as a dietary supplement, though the FDA has issued warnings about its safety. However, it is scheduled or restricted in several countries including Australia, Hungary, Italy, and Lithuania due to abuse and dependence potential. In the US, it exists in a regulatory gray zone, widely available despite known risks.

Phenibut vs baclofen — what is the difference?

Both are GABA-B receptor agonists with similar mechanisms, but phenibut is a dietary supplement not FDA-approved for medical use, while baclofen is a prescription medication approved for spasticity. Phenibut crosses the blood-brain barrier more readily due to its phenyl group and LAT1 transport, resulting in more pronounced psychoactive effects. Baclofen has more established clinical dosing and safety data, whereas phenibut products vary widely in purity and potency, and phenibut carries higher documented abuse potential.

How long does phenibut withdrawal last?

Phenibut withdrawal typically begins 3–24 hours after the last dose, peaks within 2–5 days, and acute symptoms may last 1–2 weeks. However, protracted withdrawal symptoms such as anxiety, insomnia, and cognitive difficulties can persist for weeks to months. Severity depends on dose, duration of use, and rapidity of discontinuation. Medically supervised tapering over weeks to months, sometimes with baclofen or benzodiazepine support, reduces the risk of severe complications including seizures.

Conditions it is used for

Anxiety disordersInsomniaPost-traumatic stress disorderVestibular disordersMotion sicknessAlcohol withdrawal syndromeChronic fatigue syndromeSocial anxiety disorder
baclofengabapentinpregabalindiazepamalprazolamlorazepamclonazepamacamprosate

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06BX22

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.